FDA Approves Stribild Efficacy Supplement

"On December 17, [2014], the Indications and Usage section of the STRIBILD (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300mg) label was updated to include patients who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure in order to replace their current regimen. Patients should have no known substitutions associated with resistance to the individual components of STRIBILD."   More information is available:   FDA: Press release AIDSinfo: Patient fact sheet on Stribild